title: RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial.
authors.affiliation: Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Martin
authors.affiliation: AstraZeneca, Cambridge, UK.
authors.forename: John
authors.initials: J
authors.lastname: Boyer
authors.affiliation: AstraZeneca, Alderley Park, Cheshire, UK.
authors.forename: Mary
authors.initials: M
authors.lastname: Stuart
authors.affiliation: "Sandro Pitigliani"  Department of Medical Oncology, Hospital of Prato, Italy.
authors.forename: Angelo
authors.initials: A
authors.lastname: di Leo
mesh_terms: D018931:Antineoplastic Agents, Hormonal; D000077267:Fulvestrant; D011960:Receptors, Estrogen
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D000077267:Fulvestrant